Kodiak Sciences Inc. (KOD) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-31
What protects it: the moat
It retains global rights to its candidates and utilizes Ursus, a custom-built facility dedicated to manufacturing antibody biopolymer conjugates.
It maintains full control over its intellectual property by retaining global rights to make, use, and sell its product candidates. This structure is intended to preserve future value and allow for faster decision-making compared to companies that license their platforms early.
To secure its supply chain, it commissioned Ursus, a specialized manufacturing suite designed specifically for its ABC technology. This dedicated capacity serves as a barrier against rivals who may lack the specialized infrastructure required to produce high drug-antibody ratio (DAR) medicines.
What growth costs
It funds Phase 3 trials like PEAK and PINNACLE while managing an 8-year manufacturing agreement for its custom Ursus facility.
Its growth is driven by heavy investment in late-stage clinical programs for Zenkuda, KSI-501, and KSI-101. These trials require significant capital for patient enrollment and manufacturing material for indications like wet AMD and MESI.
Manufacturing costs are tied to a long-term collaboration with Lonza. This includes an initial 8-year commitment for the Ursus facility, which can be extended to 16 years, ensuring the company has the high-volume capacity needed if its biologics receive market approval.
About Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.